Form 8-K - Current report:
SEC Accession No. 0001564590-21-047531
Filing Date
2021-09-10
Accepted
2021-09-10 07:08:46
Documents
14
Period of Report
2021-09-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-8k_20210910.htm   iXBRL 8-K 36480
2 EX-99.1 omga-ex991_6.htm EX-99.1 182139
3 GRAPHIC gstiduxhlop0000001.jpg GRAPHIC 67287
  Complete submission text file 0001564590-21-047531.txt   452952

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA omga-20210910.xsd EX-101.SCH 5705
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE omga-20210910_lab.xml EX-101.LAB 19323
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE omga-20210910_pre.xml EX-101.PRE 11498
7 EXTRACTED XBRL INSTANCE DOCUMENT omga-8k_20210910_htm.xml XML 3545
Mailing Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140
Business Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 211245834
SIC: 2836 Biological Products, (No Diagnostic Substances)